Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aroa BiosurgeryASX:ARX 57 3-Year EBITDA Growth Rate is 44.20% as of Mar. 2026, which is 14% above its 10-year median of 38.80. GuruFocus rates ASX:ARX with a GF Score™ of 57/100 and a GF Value™ of A$0.83 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 690 Medical Devices & Instruments companies, Aroa Biosurgery ranks better than 85.8% on this metric.
During the past 12 months, Aroa Biosurgery's average EBITDA Per Share Growth Rate was 237.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 44.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aroa Biosurgery was 44.20% per year. The lowest was 33.40% per year. And the median was 38.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Aroa Biosurgery 3-Year EBITDA Growth Rate Related Terms
ASX:ARX vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Aroa Biosurgery's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 44.20% mean?
Aroa Biosurgery (ASX:ARX) has a 3-Year EBITDA Growth Rate of 44.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aroa Biosurgery and its competitors. This is 14% above median its historical median of 38.80. Over the past decade, Aroa Biosurgery's 3-Year EBITDA Growth Rate has ranged from 33.40 to 44.20. According to the industry distribution chart, Aroa Biosurgery ranks #98 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 14.2%.
Is Aroa Biosurgery's 3-Year EBITDA Growth Rate too high?
Aroa Biosurgery's current 3-Year EBITDA Growth Rate of 44.20% is 14% above median its 10-year median of 38.80. Over the past 10 years, this metric has ranged from a low of 33.40 to a high of 44.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Aroa Biosurgery's value of 44.20% is 439% above this industry median. Based on the distribution chart, Aroa Biosurgery ranks #98 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Aroa Biosurgery has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #98 out of 690 companies for 3-Year EBITDA Growth Rate. This places Aroa Biosurgery in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Aroa Biosurgery's value of 44.20% is 439% above this benchmark. Historically, Aroa Biosurgery's own 3-Year EBITDA Growth Rate has ranged from 33.40 to 44.20 over the past decade. While the company's 10-year median is 38.80 vs. the industry median of 8.20, Aroa Biosurgery has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current 3-Year EBITDA Growth Rate of 44.20% is 439% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current 3-Year EBITDA Growth Rate is 44.20%, which is 14% above median its own 10-year median of 38.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.83, compared to a current price of A$0.58 — trading 30.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 44.20%, which is 14% above median its 10-year median of 38.80 and 439% above the Medical Devices & Instruments industry median of 8.20. Aroa Biosurgery's overall GF Score™ is 57/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current 3-Year EBITDA Growth Rate is 44.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.58 is trading 30.1% below its estimated GF Value™ of A$0.83.
GuruFocus considers Aroa Biosurgery to be Significantly Undervalued.
Key valuation signals for ASX:ARX:
3-Year EBITDA Growth Rate: 44.20% (14% above median its 10-year median of 38.80)
GF Value™: A$0.83 vs. price of A$0.58 (30.1% below fair value)
Industry Position: 439% above the Medical Devices & Instruments median (#98 of 690)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
57GF Score
Get the complete analysis for ASX:ARX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
